Symbols / CPHI
CPHI Chart
About
China Pharma Holdings, Inc. develops, manufactures, and markets pharmaceutical products for human use in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection for edema diseases, hypertension, acute renal failure, hyperkalemia, hypercalcemia, and acute drug poisoning; and Candesartan for hypertension. It offers Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and Pseudophedrine Hydrochlorida sustained release tablets. It offers Hepatocyte growth-promoting factors, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Additionally, the company provides Vitamin B6 injection; Granisetron Hydrochloride injection for nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. It supplies its products to hospitals and OTC pharmacies through provincial and municipal pharmaceutical logistics companies. The company is based in Haikou, the People's Republic of China.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Drug Manufacturers - Spe | Market Cap | 3.08M |
| Enterprise Value | 6.38M | Income | -3.19M | Sales | 4.05M |
| Book/sh | 1.66 | Cash/sh | 0.05 | Dividend Yield | — |
| Payout | 0.00% | Employees | 224 | IPO | — |
| P/E | — | Forward P/E | — | PEG | — |
| P/S | 0.76 | P/B | 0.37 | P/C | — |
| EV/EBITDA | -3.91 | EV/Sales | 1.57 | Quick Ratio | 0.08 |
| Current Ratio | 0.35 | Debt/Eq | 42.91 | LT Debt/Eq | — |
| EPS (ttm) | -1.02 | EPS next Y | — | EPS Growth | — |
| Revenue Growth | -31.30% | Earnings | 2011-11-10 16:00 | ROA | -13.17% |
| ROE | -42.98% | ROIC | — | Gross Margin | -10.94% |
| Oper. Margin | -83.01% | Profit Margin | -78.72% | Shs Outstand | 5.02M |
| Shs Float | 2.34M | Short Float | 0.50% | Short Ratio | 0.66 |
| Short Interest | — | 52W High | 3.20 | 52W Low | 0.59 |
| Beta | 1.13 | Avg Volume | 57.98K | Volume | 2.09K |
| Target Price | — | Recom | None | Prev Close | $0.62 |
| Price | $0.61 | Change | -1.46% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.61
Latest analyst target
3. DCF / Fair value
$3.65
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.61
Low
—
High
—
Mean
—
- China Pharma shareholders approve director elections and reverse stock split authorization - Investing.com ue, 06 Jan 2026 08
- Aspire Biopharma (Nasdaq: ASBP) advances licensing talks after 16 CPHI meetings - Stock Titan hu, 06 Nov 2025 08
- 12 Health Care Stocks Moving In Monday's After-Market Session - Sahm ue, 03 Feb 2026 08
- China Pharma Acquires Topiroxostat Patent Via Equity Issuance - TipRanks ue, 10 Feb 2026 08
- CPHI 2025 Awards Spotlight Breakthroughs in Pharmaceutical Manufacturing and API Development - PharmTech.com Wed, 29 Oct 2025 07
- CPHI Frankfurt 2025 Highlights Global Pharma Innovation and Manufacturing Leadership - BioPharm International ue, 21 Oct 2025 07
- China Pharma Announces 1-for-10 Reverse Stock Split - Nasdaq Sun, 06 Apr 2025 07
- 12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga Wed, 04 Feb 2026 08
- What Is a 1‑for‑10 Reverse Stock Split? - Schaeffer's Investment Research hu, 03 Jul 2025 07
- Can CPHI sustain its profitability - Insider Selling & Weekly Momentum Stock Picks - mfd.ru Fri, 20 Feb 2026 23
- China Pharma stockholders approve reverse split, governance changes - TipRanks ue, 06 Jan 2026 08
- West Pharma (NYSE: WST) debuts Synchrony PFS for biologics, available Jan 2026 - Stock Titan Mon, 27 Oct 2025 07
- CPHI Frankfurt Reveals 2025 Pharma Awards Finalists for Bio/Pharma Development - PharmTech.com Mon, 22 Sep 2025 07
- Aspire Biopharma reports positive reception at CPHI Frankfurt event - Investing.com hu, 06 Nov 2025 08
- Why Keysight Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket - Benzinga ue, 25 Nov 2025 08
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -1.96M | -7.32K | -931.54K | -24.87K |
| TotalUnusualItems | -5.70K | 15.76K | 93.85K | 255.22K |
| TotalUnusualItemsExcludingGoodwill | -5.70K | 15.76K | 93.85K | 255.22K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -4.74M | -3.08M | -3.97M | -3.40M |
| ReconciledDepreciation | 2.62M | 2.75M | 2.70M | 3.09M |
| ReconciledCostOfRevenue | 6.51M | 7.29M | 8.60M | 9.29M |
| EBITDA | -1.96M | 8.44K | -837.69K | 230.34K |
| EBIT | -4.58M | -2.75M | -3.54M | -2.86M |
| NetInterestIncome | -147.50K | -327.00K | -423.86K | -538.97K |
| InterestExpense | 154.14K | 333.60K | 434.62K | 542.00K |
| InterestIncome | 6.64K | 6.60K | 10.76K | 3.04K |
| NormalizedIncome | -4.73M | -3.09M | -4.07M | -3.65M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -4.74M | -3.08M | -3.97M | -3.40M |
| TotalExpenses | 9.11M | 9.78M | 11.75M | 12.76M |
| TotalOperatingIncomeAsReported | -4.59M | -2.75M | -3.55M | -2.86M |
| DilutedAverageShares | 1.75M | 338.36K | 105.14K | 92.26K |
| BasicAverageShares | 1.75M | 338.36K | 105.14K | 92.26K |
| DilutedEPS | -2.70 | -9.10 | -37.80 | -37.00 |
| BasicEPS | -2.70 | -9.10 | -37.80 | -37.00 |
| DilutedNIAvailtoComStockholders | -4.74M | -3.08M | -3.97M | -3.40M |
| NetIncomeCommonStockholders | -4.74M | -3.08M | -3.97M | -3.40M |
| NetIncome | -4.74M | -3.08M | -3.97M | -3.40M |
| NetIncomeIncludingNoncontrollingInterests | -4.74M | -3.08M | -3.97M | -3.40M |
| NetIncomeContinuousOperations | -4.74M | -3.08M | -3.97M | -3.40M |
| TaxProvision | 0.00 | 0.00 | 0.00 | 0.00 |
| PretaxIncome | -4.74M | -3.08M | -3.97M | -3.40M |
| OtherIncomeExpense | -5.70K | 15.76K | 93.85K | 255.22K |
| SpecialIncomeCharges | -5.70K | 15.76K | 93.85K | 255.22K |
| WriteOff | 5.70K | -15.76K | -93.85K | -255.22K |
| NetNonOperatingInterestIncomeExpense | -147.50K | -327.00K | -423.86K | -538.97K |
| InterestExpenseNonOperating | 154.14K | 333.60K | 434.62K | 542.00K |
| InterestIncomeNonOperating | 6.64K | 6.60K | 10.76K | 3.04K |
| OperatingIncome | -4.58M | -2.77M | -3.64M | -3.12M |
| OperatingExpense | 2.60M | 2.49M | 3.15M | 3.46M |
| ResearchAndDevelopment | 283.94K | 240.08K | 185.86K | 318.96K |
| SellingGeneralAndAdministration | 2.31M | 2.25M | 2.96M | 3.15M |
| SellingAndMarketingExpense | 528.82K | 780.33K | 1.07M | 1.50M |
| GeneralAndAdministrativeExpense | 1.78M | 1.47M | 1.89M | 1.65M |
| OtherGandA | 1.78M | 1.47M | 1.89M | 1.65M |
| GrossProfit | -1.99M | -281.08K | -493.92K | 349.27K |
| CostOfRevenue | 6.51M | 7.29M | 8.60M | 9.29M |
| TotalRevenue | 4.53M | 7.01M | 8.10M | 9.64M |
| OperatingRevenue | 4.53M | 7.01M | 8.10M | 9.64M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 3.26M | 1.06M | 149.82K | 94.68K |
| ShareIssued | 3.26M | 1.06M | 149.82K | 94.68K |
| NetDebt | 2.92M | 3.09M | 6.69M | 7.50M |
| TotalDebt | 3.59M | 4.63M | 8.76M | 12.49M |
| TangibleBookValue | 660.63K | 3.80M | 2.08M | 5.43M |
| InvestedCapital | 11.30M | 11.97M | 13.01M | 18.38M |
| WorkingCapital | -1.75M | -823.73K | -6.77M | -1.42M |
| NetTangibleAssets | 660.63K | 3.80M | 2.08M | 5.43M |
| CapitalLeaseObligations | 39.32K | 117.64K | 40.45K | 129.46K |
| CommonStockEquity | 7.75M | 7.45M | 4.29M | 6.02M |
| TotalCapitalization | 9.14M | 8.87M | 4.29M | 11.27M |
| TotalEquityGrossMinorityInterest | 7.75M | 7.45M | 4.29M | 6.02M |
| StockholdersEquity | 7.75M | 7.45M | 4.29M | 6.02M |
| OtherEquityInterest | -180.00K | |||
| GainsLossesNotAffectingRetainedEarnings | 11.32M | 11.45M | 11.57M | 12.56M |
| OtherEquityAdjustments | 11.32M | 11.45M | 11.57M | 12.56M |
| RetainedEarnings | -44.03M | -39.29M | -36.21M | -32.24M |
| AdditionalPaidInCapital | 40.60M | 35.28M | 28.93M | 25.65M |
| CapitalStock | 32.62K | 10.62K | 1.50K | 47.34K |
| CommonStock | 32.62K | 10.62K | 1.50K | 47.34K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 7.14M | 9.01M | 13.49M | 16.63M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 2.12M | 2.19M | 754.70K | 6.12M |
| NonCurrentDeferredLiabilities | 731.20K | 742.11K | 754.70K | 824.41K |
| NonCurrentDeferredTaxesLiabilities | 731.20K | 742.11K | 754.70K | 824.41K |
| LongTermDebtAndCapitalLeaseObligation | 1.39M | 1.45M | 0.00 | 5.29M |
| LongTermCapitalLeaseObligation | 0.00 | 39.91K | 0.00 | 44.18K |
| LongTermDebt | 1.39M | 1.41M | 5.25M | |
| CurrentLiabilities | 5.02M | 6.82M | 12.74M | 10.51M |
| CurrentDeferredLiabilities | 162.21K | 90.51K | 520.29K | 210.03K |
| CurrentDeferredRevenue | 162.21K | 90.51K | 520.29K | 210.03K |
| CurrentDebtAndCapitalLeaseObligation | 2.20M | 3.18M | 8.76M | 7.19M |
| CurrentCapitalLeaseObligation | 39.32K | 77.73K | 40.45K | 85.28K |
| CurrentDebt | 2.16M | 3.10M | 8.72M | 7.11M |
| OtherCurrentBorrowings | 2.16M | 3.10M | 8.72M | 7.11M |
| LineOfCredit | 0.00 | |||
| PensionandOtherPostRetirementBenefitPlansCurrent | 1.59M | 1.26M | 372.58K | 327.03K |
| PayablesAndAccruedExpenses | 1.07M | 2.29M | 3.09M | 2.78M |
| CurrentAccruedExpenses | 247.16K | 298.83K | 404.81K | 298.45K |
| Payables | 820.58K | 1.99M | 2.68M | 2.48M |
| OtherPayable | 1.24M | 951.51K | 715.51K | |
| TotalTaxPayable | 595.48K | 1.03M | 1.07M | 841.62K |
| AccountsPayable | 225.11K | 966.42K | 667.08K | 926.75K |
| TotalAssets | 14.89M | 16.47M | 17.78M | 22.65M |
| TotalNonCurrentAssets | 11.62M | 10.47M | 11.82M | 13.56M |
| GoodwillAndOtherIntangibleAssets | 7.09M | 3.65M | 2.21M | 589.62K |
| OtherIntangibleAssets | 7.09M | 3.65M | 2.21M | 589.62K |
| NetPPE | 4.53M | 6.82M | 9.61M | 12.97M |
| AccumulatedDepreciation | -32.10M | -30.39M | -28.35M | -28.16M |
| GrossPPE | 36.63M | 37.21M | 37.96M | 41.13M |
| OtherProperties | 38.30K | 116.61K | 39.05K | 127.96K |
| MachineryFurnitureEquipment | 27.49M | 27.86M | 28.53M | 30.74M |
| BuildingsAndImprovements | 9.10M | 9.23M | 9.39M | 10.26M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 3.27M | 6.00M | 5.96M | 9.09M |
| PrepaidAssets | 96.29K | 112.27K | 522.33K | 59.26K |
| Inventory | 2.27M | 3.73M | 2.95M | 3.34M |
| InventoriesAdjustmentsAllowances | -574.07K | -129.42K | ||
| FinishedGoods | 1.62M | 1.56M | 551.00K | 585.72K |
| WorkInProcess | 340.40K | 413.60K | 557.15K | 622.38K |
| RawMaterials | 880.57K | 1.89M | 1.84M | 2.13M |
| Receivables | 281.07K | 728.31K | 464.45K | 835.40K |
| OtherReceivables | 30.29K | 157.94K | 29.14K | 29.56K |
| NotesReceivable | 18.64K | 65.92K | 13.78K | 91.36K |
| AccountsReceivable | 232.14K | 504.45K | 421.53K | 714.48K |
| AllowanceForDoubtfulAccountsReceivable | -13.59M | -13.79M | -16.74M | -18.31M |
| GrossAccountsReceivable | 13.82M | 14.29M | 17.16M | 19.03M |
| CashCashEquivalentsAndShortTermInvestments | 626.88K | 1.42M | 2.03M | 4.86M |
| CashAndCashEquivalents | 626.88K | 1.42M | 2.03M | 4.86M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -758.08K | -711.20K | -811.51K | -687.89K |
| RepaymentOfDebt | -492.76K | -1.49M | -2.14M | -5.41M |
| IssuanceOfDebt | 520.11K | 1.56M | 593.93K | 10.01M |
| CapitalExpenditure | -291.72K | -11.52K | -401.96K | -438.06K |
| InterestPaidSupplementalData | 86.77K | 92.44K | 141.80K | 218.23K |
| IncomeTaxPaidSupplementalData | 0.00 | 0.00 | 0.00 | 0.00 |
| EndCashPosition | 626.88K | 1.42M | 2.03M | 4.86M |
| BeginningCashPosition | 1.42M | 2.03M | 4.86M | 957.65K |
| EffectOfExchangeRateChanges | -66.23K | 31.93K | -247.57K | -8.44K |
| ChangesInCash | -730.73K | -638.06K | -2.58M | 3.91M |
| FinancingCashFlow | 27.35K | 73.14K | -1.77M | 4.60M |
| CashFlowFromContinuingFinancingActivities | 27.35K | 73.14K | -1.77M | 4.60M |
| NetOtherFinancingCharges | -223.01K | |||
| NetIssuancePaymentsOfDebt | 27.35K | 73.14K | -1.55M | 4.60M |
| NetShortTermDebtIssuance | 30.57K | 28.96K | 5.01M | |
| ShortTermDebtPayments | -2.14M | -2.53M | ||
| ShortTermDebtIssuance | 30.57K | 28.96K | 5.01M | |
| NetLongTermDebtIssuance | 27.35K | 73.14K | -1.55M | -414.24K |
| LongTermDebtPayments | -492.76K | -1.49M | -2.14M | -5.41M |
| LongTermDebtIssuance | 520.11K | 1.56M | 593.93K | 5.00M |
| InvestingCashFlow | -291.72K | -11.52K | -401.96K | -438.06K |
| CashFlowFromContinuingInvestingActivities | -291.72K | -11.52K | -401.96K | -438.06K |
| NetIntangiblesPurchaseAndSale | -253.31K | 0.00 | ||
| PurchaseOfIntangibles | -253.31K | 0.00 | ||
| NetPPEPurchaseAndSale | -38.41K | -11.52K | -401.96K | -438.06K |
| PurchaseOfPPE | -38.41K | -11.52K | -401.96K | -438.06K |
| OperatingCashFlow | -466.36K | -699.69K | -409.55K | -249.84K |
| CashFlowFromContinuingOperatingActivities | -466.36K | -699.69K | -409.55K | -249.84K |
| ChangeInWorkingCapital | 1.20M | -396.18K | 878.34K | 51.79K |
| ChangeInOtherWorkingCapital | 73.72K | -423.26K | 339.66K | -520.41K |
| ChangeInOtherCurrentLiabilities | 0.00 | |||
| ChangeInPayablesAndAccruedExpense | -301.87K | 569.82K | 504.46K | 82.53K |
| ChangeInPayable | -301.87K | 569.82K | 504.46K | 82.53K |
| ChangeInAccountPayable | -733.92K | 312.05K | -187.73K | -332.78K |
| ChangeInPrepaidAssets | 14.47K | 412.34K | -484.68K | 23.30K |
| ChangeInInventory | 1.61M | -17.06K | 689.10K | 1.01M |
| ChangeInReceivables | -197.71K | -938.02K | -170.19K | -545.53K |
| OtherNonCashItems | 5.70K | -15.76K | 250.00K | |
| StockBasedCompensation | 0.00 | 78.27K | 15.24K | |
| AssetImpairmentCharge | 450.74K | -7.97K | -93.85K | -255.22K |
| DepreciationAmortizationDepletion | 2.62M | 2.75M | 2.70M | 3.09M |
| DepreciationAndAmortization | 2.62M | 2.75M | 2.70M | 3.09M |
| AmortizationCashFlow | 447.25K | 223.80K | 36.56K | 38.11K |
| AmortizationOfIntangibles | 447.25K | 223.80K | 36.56K | 38.11K |
| Depreciation | 2.17M | 2.53M | 2.66M | 3.05M |
| OperatingGainsLosses | 45.38K | |||
| GainLossOnSaleOfPPE | 0.00 | 45.38K | 0.00 | |
| NetIncomeFromContinuingOperations | -4.74M | -3.08M | -3.97M | -3.40M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for CPHI
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|